Tempest Therapeutics, Inc. (TPST)
$1.08+$0.32 (+42.97%) Latest session
Justin Trojanowski - Officer
Nicholas Maestas - OfficerTempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 3 | 694,446 | $500K |
11 Form 4 filings on record, the earliest from Jan 28, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Matthew Angel - Officer | Open-market purchase | Common Stock | 231,482 | $2.16 | $500K | |
| Matthew Angel - Officer | Open-market purchase | Series A Warrant (right to buy) | 231,482 | - | - | |
| Matthew Angel - Officer | Open-market purchase | Series B Warrant (right to buy) | 231,482 | - | - | |
| John D. Yee | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| William Drake Richey | Grant or award | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| Justin Trojanowski - Officer | Grant or award | Employee Stock Option (right to buy) | 22,000 | $0.00 | - | |
| Nicholas Maestas - Officer | Grant or award | Employee Stock Option (right to buy) | 140,000 | $0.00 | - | |
| Matthew Angel - Officer | Open-market purchase | Common Stock | 231,482 | $2.16 | $500K | |
| Matthew Angel - Officer | Grant or award | Employee Stock Option (right to buy) | 269,621 | $0.00 | - | |
 Ronit Simantov | Grant or award | Stock Option (right to buy) | 1,230 | $0.00 | - | |
 Michael Raab | Grant or award | Stock Option (right to buy) | 1,230 | $0.00 | - | |
| Geoffrey Nichol | Grant or award | Stock Option (right to buy) | 1,230 | $0.00 | - | |
 Christine A. Pellizzari | Grant or award | Stock Option (right to buy) | 1,230 | $0.00 | - |
Tempest Therapeutics, Inc. (TPST) had 1 insider filing in the last 90 days, with the most recent on 2026-06-23. The full record for TPST runs to 11 Form 4 filings, the earliest from 2026-01-28. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
3 insider purchases of TPST were filed in the last 90 days, totaling $500K.
No insider sales of TPST were filed in the last 90 days.
This page tracks TPST Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TPST to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
